Raymond James Forecasts Strong Price Appreciation for ADMA Biologics (NASDAQ:ADMA) Stock

ADMA Biologics (NASDAQ:ADMA) had its price objective raised by equities research analysts at Raymond James from $18.00 to $25.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “strong-buy” rating on the biotechnology company’s stock. Raymond James’ price target would indicate a potential upside of 10.52% from the stock’s current price.

A number of other research analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of ADMA Biologics in a research report on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $21.25.

ADMA Biologics Trading Up 14.7 %

NASDAQ ADMA opened at $22.62 on Friday. The firm has a market capitalization of $5.27 billion, a PE ratio of 161.57 and a beta of 0.64. ADMA Biologics has a one year low of $3.60 and a one year high of $23.52. The company has a 50-day simple moving average of $18.12 and a 200-day simple moving average of $13.89. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share. On average, equities analysts forecast that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 136,861 shares of ADMA Biologics stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the transaction, the director now owns 467,305 shares in the company, valued at approximately $8,070,357.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC acquired a new position in ADMA Biologics in the second quarter worth approximately $29,000. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics during the 3rd quarter worth $30,000. EntryPoint Capital LLC bought a new position in shares of ADMA Biologics during the 1st quarter valued at $31,000. CWM LLC boosted its holdings in ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in ADMA Biologics during the second quarter worth $93,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.